Comparative Pharmacokinetics of Seven Major Compounds in Normal and Atherosclerosis Mice after Oral Administration of Simiao Yong'an Decoction. (28th April 2022)

• Record Type: Journal Article
• Authors: Sun, Ke-han; Yang, Man-fang; Xu, Xin-rui; Li, Yang; Gao, Zhao; Zhang, Qing-yue; Li, Hui; Wang, Shu-qi; Lou, Li-xia; Wu, Ai-ming; Jin, Qiu-shuo; Wu, Sheng-xian; Nie, Bo
• Other Names: Kang Li-Ping Academic Editor.
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2022(2022)
• Publication Date: 2022-04-28
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2022/4604601
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : Simiao Yong'an decoction (SMYAD), a classic traditional Chinese medicine formula, has been used to treat atherosclerosis (AS) in clinical in China, but its therapeutic mechanism and pharmacodynamic material basis are not clear. In this study, the AS model was caused by a high-fat diet and perivascular carotid collar placement (PCCP), and SMYAD was orally administered to the model and normal mice. A rapid, sensitive, selective, and reliable method using ultrahigh-performance liquid chromatography (UHPLC) system combined with a Q Exactive HF-X mass spectrometer (UHPLC-Q Exactive HF-X MS) was established and validated for the simultaneous determination of seven compounds, including harpagide, chlorogenic acid, swertiamarin, sweroside, angoroside C, liquiritin, and isoliquiritigenin in the plasma of normal and AS mice. The specificity, linearity, precision, accuracy, recovery, and stability of the method were all within the acceptable criteria. The results showed that some pharmacokinetic behaviors of harpagide, chlorogenic acid, and isoliquiritigenin were significantly different among the two groups of mice. The specific parameter changes were harpagide (AUC0– t and AUC0–∞ were 11075.09 ± 2132.38 and 16221.95 ± 5622.42 ng·mL −1 ·h, respectively; CLz/F was 2.45 ± 0.87 L/h/mg), chlorogenic acid ( t 1/2 was 21.59 ± 9.16 h; AUC0–∞ was 2637.51 ± 322.54 ng·mL −1 ·h; CLz/F was 13.49 ± 1.81 L/h/mg) and isoliquiritigenin (AUC0– t and AUC0–∞ were 502.25 ± 165.65 and 653.68 ± 251.34 ng·mL −1 ·h, respectively; CLz/F was 62.16 ± 23.35 L/h/mg) were altered under the pathological status of AS. These differences might be partly ascribed to the changes in gastrointestinal microbiota, nonspecific drug transporters, and cytochrome P450 activity under the AS state, providing research ideas and experimental basis for pharmacological effects and pharmacodynamic material basis.